157 related articles for article (PubMed ID: 27612501)
21. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
22. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
23. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.
Andrésdóttir G; Jensen ML; Carstensen B; Parving HH; Rossing K; Hansen TW; Rossing P
Diabetes Care; 2014 Jun; 37(6):1660-7. PubMed ID: 24623028
[TBL] [Abstract][Full Text] [Related]
24. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
25. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
26. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
27. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Miao Y; Ottenbros SA; Laverman GD; Brenner BM; Cooper ME; Parving HH; Grobbee DE; Shahinfar S; de Zeeuw D; Lambers Heerspink HJ
Hypertension; 2011 Jul; 58(1):2-7. PubMed ID: 21632472
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics.
de Boer IH; Zelnick LR; Lin J; Schaumberg D; Wang L; Ruzinski J; Friedenberg G; Duszlak J; Bubes VY; Hoofnagle AN; Thadhani R; Glynn RJ; Buring JE; Sesso HD; Manson JE
Contemp Clin Trials; 2018 Nov; 74():11-17. PubMed ID: 30282055
[TBL] [Abstract][Full Text] [Related]
29. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients?
Fontseré N; Salinas I; Bonal J; Bayés B; Riba J; Torres F; Rios J; Sanmartí A; Romero R
Nephrol Dial Transplant; 2006 Aug; 21(8):2152-8. PubMed ID: 16702203
[TBL] [Abstract][Full Text] [Related]
30. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Andersen S; van Nieuwenhoven FA; Tarnow L; Rossing P; Rossing K; Wieten L; Goldschmeding R; Parving HH
Kidney Int; 2005 Jun; 67(6):2325-9. PubMed ID: 15882275
[TBL] [Abstract][Full Text] [Related]
31. Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
Kimura G
Clin Exp Nephrol; 2006 Sep; 10(3):226-7. PubMed ID: 17009082
[No Abstract] [Full Text] [Related]
32. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
33. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Ruggenenti P; Lauria G; Iliev IP; Fassi A; Ilieva AP; Rota S; Chiurchiu C; Barlovic DP; Sghirlanzoni A; Lombardi R; Penza P; Cavaletti G; Piatti ML; Frigeni B; Filipponi M; Rubis N; Noris G; Motterlini N; Ene-Iordache B; Gaspari F; Perna A; Zaletel J; Bossi A; Dodesini AR; Trevisan R; Remuzzi G;
Hypertension; 2011 Nov; 58(5):776-83. PubMed ID: 21931073
[TBL] [Abstract][Full Text] [Related]
34. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
35. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
36. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
37. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
[TBL] [Abstract][Full Text] [Related]
38. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
[TBL] [Abstract][Full Text] [Related]
39. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
[TBL] [Abstract][Full Text] [Related]
40. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
